Highmark Health’s VITAL Innovation Platform testing benefits of innovations from Omron® Healthcare related to daily control of hypertension and from Sensible Medical related to measurement of lung fluid in patients with congestive heart failure

VITAL program will provide real-​world evidence related to patient expe­ri­ence, care outcomes and cost impact

PITTSBURGH; LAKE FOREST, ILL; TENAFLY, NJ (Dec. 12, 2018) – Highmark Health announced today that through its VITAL Innovation Platform, it is testing two early-​stage health inno­va­tions: Omron Healthcare’s Hypertension Management Platform related to daily control of hyper­ten­sion and Sensible Medical’s ReDSTM (Remote Dielectric Sensing) Fluid Monitoring System related to measure­ment of lung fluid in patients with conges­tive heart failure.

A test-​and-​learn plat­form powered by Highmark Health’s robust inte­grated delivery and financing system, VITAL rigor­ously tests health inno­va­tions in clin­ical settings and through claims-​level and clin­ical data, produces real-​world evidence related to patient expe­ri­ence, care outcomes and cost impact.

The VITAL program is testing Omron’s Hypertension Management Program through July of 2019 among 200 patients with hyper­ten­sion. This plat­form uses auto­mated blood pres­sure moni­tors oper­ated daily by patients in their envi­ron­ments, and through the Omron Hypertension Management app, sends clin­ical data to Omron’s Dr. Dashboard, allowing clin­i­cians to specif­i­cally assess the char­ac­ter­is­tics of the hyper­ten­sion and to risk-​stratify patients. High-​risk patients can then be iden­ti­fied for earlier inter­ven­tion, poten­tially resulting in improved health outcomes, reduc­tion in acute events and an overall reduc­tion in the cost of patient care. 

Omron’s Hypertension Management Platform

According to the American Heart Association and the American College of Cardiology, nearly half of U.S. adults have hyper­ten­sion, one of the leading risk factors of heart attack and stroke. Spearheading the Omron test is lead inves­ti­gator Dr. Francis Colangelo of Premier Medical Associates in Monroeville, Pa.

In addi­tion, the VITAL program is testing Sensible Medical’s ReDS Fluid Monitoring System through July of 2019 among 100 patients with recent conges­tive heart failure admis­sions who are being discharged from an Allegheny Health Network hospital to a skilled nursing facility. The ReDS system features a nonin­va­sive vest” that within 90 seconds can supple­ment the stetho­scope by using radio frequency tech­nology to provide an objec­tive measure of conges­tion in the lungs related to pulmonary edema. If threshold levels of fluids exist, patients would remain in the nursing facility for further treat­ment until discharge levels are met. Using the ReDS system has the poten­tial to reduce prema­ture patient discharges that can result in emer­gency rooms episodes and costly hospital read­mis­sions.

Sensible Medical’s ReDSTM Fluid Monitoring Device System

Spearheading the Sensible Medical ReDS test is lead inves­ti­gator Dr. Srinivas Murali of Allegheny Health Network’s Allegheny General Hospital in Pittsburgh.

Heart disease is the leading cause of death in the U.S., and it accounts for $200 billion in health care spending annu­ally,” said Sarah Ahmad, senior vice pres­i­dent of inno­va­tion and trans­for­ma­tion strategy for Highmark Health. A top priority of the VITAL program is discov­ering inno­v­a­tive ways to prevent and control hyper­ten­sion, as well as diag­nose and care for those living with a heart condi­tion. We look forward to working with Omron and Sensible Medical on their unique solu­tions.”

Until 2018, the VITAL plat­form had exclu­sively served as an internal plat­form for Highmark Health affil­i­ates Allegheny Health Network and the Highmark Health Plan. Resulting from its success, it has now evolved to a commer­cial model, and Omron repre­sents one of its first busi­ness part­ners.

Omron’s mission to elim­i­nate heart attack and stroke is advanced by working with Highmark Health,” said Andy Atwell, head of new busi­ness devel­op­ment, Omron Healthcare. The VITAL program creates an oppor­tu­nity to perfect our hyper­ten­sion manage­ment and physi­cian deci­sion support plat­form in the real world. VITAL provides a crit­ical frame­work for plan­ning a successful test and producing valu­able evidence for down­stream deci­sion making within Highmark Health.”

About Highmark Health’s VITAL Innovation Platform

Unless accel¬er¬ated, impor¬tant new FDA-​approved health care inno¬va¬tions can idle, awaiting the evidence needed to gain adop¬tion and market¬place access that can change the course of a patient’s diag¬nosis, or life. VITAL is the solu¬tion: a test-​and-​learn plat¬form that can help propel new health solu¬tions into the market¬place by providing the ideal envi¬ron¬ment for producing evidence. The unique VITAL Innovation Platform lever­ages Highmark Health’s posi­tion as the nation’s second largest inte­grated delivery and financing system. VITAL facil­i­tates real-​world testing of early-​stage health inno­va­tions, producing evidence related to patient expe­ri­ence, and care and cost outcomes. This evidence may accel­erate an innovation’s coverage and utiliza­tion by health plans and care delivery systems, fast-​tracking the solu­tion to patients and supporting swifter market­place adop­tion. To learn more, please visit vital​in​no​va​tion​.com.

About Highmark Health

Highmark Health, a Pittsburgh, PA-​based company, that, together with its subsidiaries and affil­i­ates, collec­tively employ more than 40,000 people and serve millions of Americans across the country, is the second largest inte­grated health care delivery and financing network in the nation based on revenue. Highmark Health is the parent company of Highmark Inc., Allegheny Health Network, and HM Health Solutions. Highmark Inc. and its subsidiaries and affil­i­ates provide health insur­ance to nearly 5 million members in Pennsylvania, West Virginia, and Delaware as well as dental insur­ance, vision care and related health prod­ucts through a national network of diver­si­fied busi­nesses that include United Concordia Companies, HM Insurance Group, and Visionworks. Allegheny Health Network is the parent company of an inte­grated delivery network that includes eight hospi­tals, more than 2,400 affil­i­ated physi­cians, ambu­la­tory surgery centers, an employed physi­cian orga­ni­za­tion, home and community-​based health services, a research insti­tute, a group purchasing orga­ni­za­tion, and health and well­ness pavil­ions in western Pennsylvania. HM Health Solutions focuses on meeting the infor­ma­tion tech­nology plat­form and other busi­ness needs of the Highmark Health enter­prise as well as unaf­fil­i­ated health insur­ance plans by providing proven busi­ness processes, expert knowl­edge and inte­grated cloud-​based plat­forms. To learn more, please visit vital​in​no​va​tion​.com/​h​i​g​h​m​a​r​k​h​e​a​l​t​h.org.

About Omron Healthcare, Inc.

Omron Healthcare, Inc. is a leading manu­fac­turer and distrib­utor of personal heart health and well­ness prod­ucts. Omron’s market-​leading prod­ucts include home blood pres­sure moni­tors and elec­trotherapy devices. Since Omron invented its first blood pres­sure moni­tors more than 40 years ago, the company has been passionate about empow­ering people to take charge of their health at home through precise tech­nology. Helping people improve their ability to live a healthier life is the heart and soul of Omron’s purpose. For more infor­ma­tion, visit omron​health​care​.com

About Sensible Medical

Sensible Medical is an Israeli medical tech­nology start-​up company that has devel­oped ReDS (Remote Dielectric Sensing) tech­nology that utilizes minia­ture medical radar to deliver accu­rate lung volume measure­ments that are corre­lated with computed tomog­raphy. Because ReDS fluid volume infor­ma­tion is accu­rate, and absolute rather than rela­tive, it is action­able data that can used to better under­stand and manage patients’ heart fail­ures. In a clin­ical study, ReDS has been shown to reduce read­mis­sion by as much as 87%. Healthcare facil­i­ties across the U.S. have also been seeing simi­larly high reduc­tions with action­able data guiding treat­ment deci­sions. For more infor­ma­tion, visit sensible​-medical​.com.